文献速递免疫规划妇幼与学校卫生

影响孕妇对新生儿呼吸道合胞病毒免疫接种接受度的因素:一项混合方法研究

Factors influencing acceptance of RSV immunization for newborns among pregnant individuals: A mixed-methods study.
PubMed 文献 · Vaccine · 2025-03-28

该研究于2023年10月至12月在魁北克通过Facebook广告招募孕妇,采用混合方法(在线调查n=803,质性访谈n=25)评估其对呼吸道合胞病毒(RSV)免疫接种的知识、态度与意愿。结果显示68.4%的参与者对RSV有一定了解,88.1%愿意孕期接种RSV疫苗,92%愿意为婴儿使用单克隆抗体,69%偏好孕期接种;保护婴儿免受严重RSV并发症是主要动机,疫苗安全性、有效性及医护人员推荐也是关键因素。质性访谈强调了对新产品的安全担忧及医护人员提供清晰循证推荐的重要性。

要点

  • 调查参与者中88.1%愿意孕期接种RSV疫苗,92%愿意为婴儿使用单克隆抗体。
  • 69%的参与者偏好孕期接种疫苗而非单克隆抗体。
  • 保护婴儿免受严重RSV并发症、疫苗安全性、有效性及医护人员推荐是接受新RSV免疫产品的主要影响因素。

核心结论

  • 孕妇对婴儿RSV免疫接种(孕期接种或单克隆抗体)表现出高度兴趣,医护人员的推荐以及关于新产品安全性和有效性的信息将是促使意图转化为行动的关键。

研究设计与样本

  • 2023年10月至12月在魁北克开展混合方法研究,通过定向Facebook广告招募孕妇;第一阶段为在线调查(n=803),采用描述性统计;第二阶段为质性访谈(n=25),采用主题分析。

主要发现

  • 调查参与者(n=803)中68.4%报告对RSV有一定了解。
  • 88.1%的参与者愿意孕期接种RSV疫苗,92%愿意为婴儿使用单克隆抗体。
  • 69%的参与者偏好孕期接种疫苗而非单克隆抗体。
  • 质性访谈(n=25)强调准父母对这些新产品的安全担忧,以及医护人员提供清晰循证推荐的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of respiratory infections and hospitalizations in Canadian infants. Recently, Health Canada approved two novel immunizing products: a vaccine given during pregnancy and a monoclonal antibody for infants. This study assessed knowledge, attitudes, and intentions regarding RSV and its prevention among pregnant individuals. METHODS: A mixed-methods study was conducted in Quebec from October to December 2023. Pregnant individuals were recruited through targeted Facebook advertisements. Data were collected in two phases: Phase 1 involved an online survey to assess knowledge of RSV, attitudes toward immunization, and intentions regarding both immunization products, followed by qualitative interviews in Phase 2 to explore factors impacting decision-making and preferences for RSV prevention. Survey data were analyzed using descriptive statistics; interview data were analyzed through thematic analysis. RESULTS: Among survey participants (n = 803), 68.4 % reported some knowledge of RSV. Intention for both immunization products was high, with 88.1 % of participants willing to receive the RSV vaccine during pregnancy and 92 %, to administer monoclonal antibodies to their infants. A majority (69 %) of participants preferred vaccination during pregnancy over monoclonal antibodies. The desire to protect their infant from severe RSV complications was a key motivating factor of acceptance of new RSV immunizing products. Other key determinants included vaccine safety, efficacy, and recommendations by healthcare providers. Qualitative interviews (n = 25) highlighted safety concerns of expectant parents about these new products. The importance of clear and evidence-based recommendations by healthcare providers was also emphasized. CONCLUSIONS: Pregnant individuals demonstrated a high level of interest in RSV immunization for infants, whether with vaccination during pregnancy or with monoclonal antibodies. Recommendations by healthcare providers and availability of information on the safety and efficacy of these new products will be key to move from intention to action.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gagnon D, Gubany C, Ouakki M, et al. Factors influencing acceptance of RSV immunization for newborns among pregnant individuals: A mixed-methods study. Vaccine. 2025. PMID: 40156958. doi:10.1016/j.vaccine.2025.127062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。